Effects of diltiazem prophylaxis on the incidence and clinical outcome of atrial arrhythmias after thoracic surgery

Objectives: We sought to determine whether early prophylaxis with an L-type calcium channel blocker reduces the incidence and morbidity associated wit h atrial fibrillation/flutter and supraventricular tachyarrhythmia after ma jor thoracic operations. Methods: In this randomized, double-blind, placebo-controlled study, 330 pa tients were given either intravenous diltiazem (n = 167) or placebo (n = 16 3) immediately after lobectomy (greater than or equal to 60 years) or pneum onectomy (greater than or equal to 18 years) and orally thereafter for 14 d ays. The primary end point with respect to efficacy was a sustained (greate r than or equal to 15 minutes) or clinically significant atrial arrhythmia during treatment. Results: Postoperative atrial arrhythmias (atrial fibrillation/flutter = 60 ; supraventricular tachyarrhythmias = 5) occurred in 25 (15%) of the 167 pa tients in the diltiazem group and 40 (25%) of the 163 patients in the place bo group (P =.03). When compared with placebo, diltiazem nearly halved the incidence of clinically significant arrhythmias (17/167 [10%] vs 31/163 [19 %], P =.02), The 2 groups did not differ in the incidence of other major po stoperative complications or overall duration or costs of hospitalization. No serious adverse effects caused by diltiazem were seen. Conclusions: After major thoracic operations, prophylactic diltiazem reduce d the incidence of clinically significant atrial arrhythmias in patients co nsidered at high risk for this complication.